Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment

Inclusion Criteria: * Infertility due to tubal factor and/or male factor * Age between 20 and 35 years with regular menstrual cycles of 21-35 days * First or second cycle in the present series of ART * BMI (body mass index) ≥ 18 ≤ 30 kg/m2 * Basal FSH (follicle stimulating hormone) \< 10 IU/L (cycle day 2-5) * E2 (estradiol) levels \< 50pg/mL (cycle day 2) * AMH (anti-mullerian hormone) ≥ 1.0 ng/ml * Antral follicle ≥ 4 to ≤ 15 follicles (both ovaries) * Presence of both ovaries and normal uterine cavity * Informed consent Exclusion Criteria: * Presence of pregnancy * Hypersensitivity to follitropin alfa * Ovarian cysts * History of ≥2 succeeding ART (assisted reproductive technology) cycles IVF (in vitro fertilization) and/or ICSI (Intracytoplasmic sperm injection) before the study cycle * Previous history of severe ovarian hyperstimulation syndrome * Presence of polycystic ovaries (PCO) * Presence of endometriosis and hydrosalpinx * Presence of uterine disorders * History of poor (\< 4 oocytes) or hyper (\> 25 oocytes) responses to FSH treatment at dose 150 IU and GnRH-antagonist (gonadotropin-releasing hormone) protocol * Premature ovarian failure * Ectopic pregnancy (3 month before the study cycle) * Presence of clinically significant systemic disease * Presence of chronic cardiovascular, hepatic, renal or pulmonary disease * Presence of endocrine disorder * Neoplasia * Male infertility without mobile spermatozoa in the ejaculate, that need MESA (Microsurgical epididymal sperm aspiration)/TESE (testicular sperm extraction)/TESA (testicular sperm aspiration) * Smoking \> 10 cigarettes/day * Narcomania, alcoholism * Planned PGS (preimplantation genetic screeneing) /PGD (preimplantation genetic diagnosis)